GSK announces data to support Cervarix® two-dose schedule for the prevention of cervical cancer in 9-14 year old girls

GlaxoSmithKline (GSK) plc today announced the results of a Phase III study of its HPV vaccine, Cervarix.
Source: GSK news - Category: Pharmaceuticals Source Type: news